GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Estrella Immunopharma ESLA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.51

+36.93%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Estrella Immunopharma

From its filings with the US Securities and Exchange Commission

SEC filings

Estrella Immunopharma is based in Emeryville, California. Its shares trade on Nasdaq under the ticker ESLA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $13.1m. At that date it held total assets of $3.2m and shareholders' equity of −$10.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
19 Jul 2021
Head office
5858 HORTON STREET, SUITE 370, EMERYVILLE, CA, 94608
Classification
Biological Products, (No Diagnostic Substances)
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Ms. Hong ZhangChairman of the Board, since 2024
  • Dr. Cheng LiuPresident, Chief Executive Officer, Director, since 2024$430,000
  • Mr. Peter XuChief Financial Officer$500,000
  • Mr. Jia DengyaoDirector
  • Dr. Marsha RobertsIndependent Director$15,000
  • Mr. Fan WuIndependent Director$15,000
  • Ms. Janelle WuIndependent Director$15,000
  • Ms. Pei XuIndependent Director$15,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Estrella Immunopharma's ARTEMIS T-cell therapies target CD19 and CD22 for blood cancers and solid tumors.
  • EB103 utilizes Eureka's ARTEMIS technology to address B-cell malignancies effectively.
  • Collaboration with Imugene Limited enhances research on EB103 for solid tumor treatments.

Weaknesses

  • Preclinical-stage development limits immediate market availability of EB103 and EB104.
  • Reliance on Eureka's ARTEMIS technology may pose dependency risks.
  • Limited product pipeline beyond EB103 and EB104 in biopharmaceutical development.

Opportunities

  • Expanding collaboration with Imugene Limited for CF33-CD19t in solid tumor research.
  • Growing demand for targeted therapies in blood cancer treatment markets.
  • Potential market entry in the US biotechnology sector for CD19-targeted therapies.

Threats

  • Competition from established biopharmaceutical companies in the US market.
  • Regulatory challenges in developing preclinical-stage therapies.
  • High R&D costs associated with biotechnology product development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.